Ellen Young, Boyd Yount, Petraleigh Pantoja, Sandra Henein, Rita M Meganck, Jennifer McBride, Jennifer E Munt, Thomas J Baric, Deanna Zhu, Trevor Scobey, Stephanie Dong, Longping V Tse, Melween I Martinez, Armando G Burgos, Rachel L Graham, Laura White, Aravinda DeSilva, Carlos A Sariol, Ralph S Baric
The four dengue virus serotypes co-circulate globally and cause significant human disease. Dengue vaccine development is challenging because some virus-specific antibodies are protective, while others are implicated in enhanced viral replication and more severe disease. Current dengue tetravalent vaccines contain four live attenuated serotypes formulated to theoretically induce balanced protective immunity. Among the number of vaccine candidates in clinical trials, only Dengvaxia is licensed for use in DENV seropositive individuals...
March 13, 2023: Nature Communications